• Abstract

    One of the most difficult conditions to treat is cancer. Chemotherapy has been a mainstay in the treatment of cancer, and many approaches have also been attempted for neurological illnesses. Withania somnifera (Dunal), a well-known plant with therapeutic use documented for centuries, is one of the plants that has been used in medicine for decades owing to its unfavorable deficiencies, including resistance to malignant cells and inefficiency in neurological illness. Many ashwagandha or winter cherry plants are a great source of anolides, which are chemicals with medicinal activity. Research has recently been conducted to better understand the wide-ranging effects of withania somnifera on neurological diseases and cancer. Withania somnifera is well recognized for its ability to mend cells and has been shown to be helpful in DNA repair processes. It also helps to prevent normal cells from dying. The possible uses and health advantages of Withania somnifera, particularly in the treatment of cancer and neurological disorders, are outlined in this article. The available information indicates that Withania somnifera is useful for slowing the course of illness and may be a useful therapeutic target for improving human health.

  • References

    1. Singh N, Bhalla M, de Jager P., Gilca M: An overview on Ashwagandha: A Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011, 8:208-213. 10.4314/ajtcam.v8i5S.9
    2. Langade D, Kanchi S, Salve J, Debnath K, Ambegaokar D: Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Insomnia and Anxiety: A Double-blind, Randomized, Placebo-controlled Study. Cureus. 2019, 11:5797. 10.7759/cureus.5797
    3. Połumackanycz M, Forencewicz A, Wesołowski M, Viapiana A: Ashwagandha (Withania somnifera L.)—The plant with proven health-promoting properties. Farm Pol. 2020, 76:442-447. 10.32383/farmpol/127824
    4. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazón J: Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules. 2009, 14:2373-2393. 10.3390/molecules14072373
    5. Dutta R, Khalil R, Green R, Mohapatra SS, Mohapatra S: Withania Somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology. Int J Mol Sci. 2019, 20:5310. 10.3390/ijms20215310
    6. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M: Alzheimer’s disease: Pathogenesis, diagnostics, and therapeutics. Int J Nanomed. 2019, 14:5541-5554. 10.2147/IJN.S200490
    7. Kurapati KRV, Atluri VSR, Samikkannu T, Nair MPN: Ashwagandha (Withania somnifera) reverses β-amyloid1-42 induced toxicity in human neuronal cells: Implications in HIV-associated neurocognitive disorders (HAND). PLoS ONE. 2013, 8:77624. 10.1371/journal.pone.0077624
    8. Pandey A, Bani S, Dutt P, Satti NK, Suri KA, Qazi GN: Multifunctional neuroprotective effect of Withanone, a compound from Withania somnifera roots in alleviating cognitive dysfunction. Cytokine. 2018, 102:211-221. 10.1016/j.cyto.2017.10.019
    9. Das R, Rauf A, Akhter S, et al.: Role of Withaferin A and Its Derivatives in the Management of Alzheimer’s Disease: Recent Trends and Future Perspectives. Molecules. 2021, 26:3696. 10.3390/molecules26123696
    10. Atluri VSR, Tiwari S, Rodriguez M, et al.: Inhibition of Amyloid-Beta production, associated neuroinflammation, and Histone Deacetylase 2-mediated epigenetic modifications prevent neuropathology in Alzheimer’s disease in vitro Model. Front Aging Neurosci. 2020, 11:342. 10.3389/fnagi.2019.00342
    11. Sehgal N, Gupta A, Valli RK, et al.: Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci USA. 2012, 109:3510-3515. 10.1073/pnas.1112209109
    12. Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA: Low-density lipoprotein receptor-related protein- 1: A serial clearance homeostatic mechanism controlling Alzheimer’s amyloid β-peptide elimination from the brain. J Neurochem. 2010, 115:1077-1089. 10.1111/j.1471-4159.2010.07002.x
    13. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK: LDL receptor-related protein 1: Unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008, 88:887-918. 10.1152/physrev.00033.2007
    14. Rauch JN, Luna G, Guzman E, et al.: LRP1 is a master regulator of tau uptake and spread. Nature. 2020, 580:381-385. 10.1038/s41586-020-2156-5
    15. Dubey S, Kallubai M, Subramanyam R: Improving the inhibition of β-amyloid aggregation by withanolide and withanoside derivatives. Int J Biol Macromol. 2021, 173:56-65. 10.1016/j.ijbiomac.2021.01.094
    16. Kuboyama T, Tohda C, Komatsu K: Withanoside IV and its active metabolite, sominone, attenuate Aβ(25-35)-induced neurodegeneration. Eur J Neurosci. 2006, 23:1417-1426. 10.1111/j.1460-9568.2006.04664.x
    17. Rabhi C, Arcile G, LeGoff G, DaCosta NC, Ouazzani J: Neuroprotective effect of CR-777, a glutathione derivative of Withaferin A, obtained through the bioconversion of Withania somnifera (L.) Dunal extract by the fungus Beauveria bassiana. Molecules. 2019, 24:4599. 10.3390/molecules24244599
    18. Mukherjee S, Kumar G, Patnaik R: Withanolide a penetrates brain via intra-nasal administration and exerts neuroprotection in cerebral ischemia reperfusion injury in mice. Xenobiotica. 2020, 50:957-966. 10.1080/00498254.2019.1709228
    19. Singh M, Ramassamy C: In vitro screening of neuroprotective activity of Indian medicinal plant Withania somnifera. J Nutr Sci. 2017, 6:54. 10.1017/jns.2017.48
    20. Bhargava P, Malik V, Liu Y, Ryu J, Kaul SC, Sundar D, Wadhwa R: Molecular Insights Into Withaferin-A-Induced Senescence: Bioinformatics and Experimental Evidence to the Role of NFκB and CARF. J Gerontol A Biol Sci Med Sci. 2019, 74:183-191. 10.1093/gerona/gly107
    21. Ahmad M, Saleem S, Ahmad AS, Ansari MA, Yousuf S, Hoda MN, Islam F: Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats. Hum Exp Toxicol. 2005, 24:137-147. 10.1191/0960327105ht509oa
    22. Wongtrakul J, Thongtan T, Kumrapich B, Saisawang C, Ketterman AJ: Neuroprotective effects of Withania somnifera in the SH-SY5Y Parkinson cell model. Heliyon. 2021, 7:08172. 10.1016/j.heliyon.2021.e08172
    23. RajaSankar S, Manivasagam T, Sankar V, Prakash S, Muthusamy R, Krishnamurti A, Surendran S: Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson’s disease model mouse. J Ethnopharmacol. 2009, 125:369-373. 10.1016/j.jep.2009.08.003
    24. DeRose F, Marotta R, Poddighe S, et al.: Functional and morphological correlates in the Drosophila LRRK2 loss-of-function model of Parkinson’s disease: Drug effects of Withania somnifera (Dunal) administration. PLoS ONE. 2016, 11:0146140. 10.1371/journal.pone.0146140
    25. RajaSankar S, Manivasagam T, Surendran S: Ashwagandha leaf extract: A potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson’s disease. Neurosci Lett. 2009, 454:11-15. 10.1016/j.neulet.2009.02.044
    26. Rojas NG, Cesarini ME, Peker G, DaPrat GA, Etcheverry JL, Gatto EM: Review of Huntington’s Disease: From Basics to Advances in Diagnosis and Treatment. J Neurol Res. 2022, 12:93-113. 10.14740/jnr721
    27. Kumar P, Kumar A: Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioural, biochemical, and mitochondrial dysfunction in an animal model of Huntington’s disease. J Med Food. 2009, 12:591-600. 10.1089/jmf.2008.0028
    28. Joshi T, Kumar V, Kaznacheyeva EV, Jana NR: Withaferin A Induces Heat Shock Response and Ameliorates Disease Progression in a Mouse Model of Huntington’s Disease. Mol Neurobiol. 2021, 58:3992-4006. 10.1007/s12035-021-02397-8
    29. Fakhri S, Piri S, Moradi SZ, Khan H: Phytochemicals Targeting Oxidative Stress, Interconnected Neuroinflammatory, and Neuroapoptotic Pathways Following Radiation. Curr Neuropharmacol. 2022, 20:836-856. 10.2174/1570159X19666210809103346
    30. Jahanbakhsh SP, Manteghi AA, Emami SA, Mahyari S, Gholampour B, Mohammadpour AH, Sahebkar A: Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial. Complement. Ther Med. 2016, 27:25-29. 10.1016/j.ctim.2016.03.018
    31. Kaurav BPS, Wanjari MM, Chandekar A, Chauhan NS, Upmanyu N: Influence of Withania somnifera on obsessive compulsive disorder in mice. Asian Pac J Trop Med. 2012, 5:380-384. 10.1016/S1995-7645(12)60063-7
    32. Haque IM, Mishra A, Kalra BS, Chawla S: Role of Standardized Plant Extracts in Controlling Alcohol Withdrawal Syndrome—An Experimental Study. Brain Sci. 2021, 11:919. 10.3390/brainsci11070919
    33. Dar NJ, Hamid A, Ahmad M: Pharmacologic overview of Withania somnifera, the Indian Ginseng. Cell Mol Life Sci. 2015, 72:4445-4460. 10.1007/s00018-015-2012-1
    34. Rasool M, Varalakshmi P: Immunomodulatory role of Withania somnifera root powder on experimental induced inflammation: An in vivo and in vitro study. Vascul Pharmacol. 2006, 44:406-410. 10.1016/j.vph.2006.01.015
    35. Sikandan A, Shinomiya T, Nagahara Y: Ashwagandha root extract exerts anti-inflammatory effects in HaCaT cells by inhibiting the MAPK/NF-κB pathways and by regulating cytokines. Int J Mol Med. 2018, 42:425-434. 10.3892/ijmm.2018.3608
    36. Kumari M, Gupta RP: In vitro antibacterial effect of Withania somnifera root extract on Escherichia coli. Vet World. 2015, 8:57. 10.14202/vetworld.2015.57-60
    37. Alam N, Hossain M, Mottalib MA, Sulaiman SA, Gan SH, Khalil MI: Methanolic extracts of Withania somnifera leaves, fruits and roots possess antioxidant properties and antibacterial activities. BMC Complement Altern Med. 2012, 12:1-8. 10.1186/1472-6882-12-175
    38. Mwitari PG, Ayeka PA, Ondicho J, Matu EN, Bii CC: Antimicrobial Activity and Probable Mechanisms of Action of Medicinal Plants of Kenya: Withania somnifera, Warbugia ugandensis, Prunus africana and Plectrunthus barbatus. PLoS ONE. 2013, 8:65619. 10.1371/journal.pone.0065619
    39. Owais M, Sharad KS, Shehbaz A, Saleemuddin M: Antibacterial efficacy of Withania somnifera (Ashwagandha) an indigenous medicinal plant against experimental murine salmonellosis. Phytomedicine. 2005, 12:229-235. 10.1016/j.phymed.2003.07.012
    40. Pandit S, Chang KW, Jeon JG: Effects of Withania somnifera on the growth and virulence properties of Streptococcus mutans and Streptococcus sobrinus at sub-MIC levels. Anaerobe. 2013, 19:1-8. 10.1016/j.anaerobe.2012.10.007
    41. Chandrasekaran S, Dayakar A, Veronica J, Sundar S, Maurya R: An in vitro study of apoptotic like death in Leishmania donovani promastigotes by withanolides. Parasitol Int. 2013, 62:253-261. 10.1016/j.parint.2013.01.007
    42. Girish KS, Machiah KD, Ushanandini S, et al.: Antimicrobial properties of a non-toxic glycoprotein (WSG) from Withania somnifera (Ashwagandha). J Basic Microbiol. 2006, 46:365-374. 10.1002/jobm.200510108
    43. Murugan R, Rajesh R, Seenivasan B, et al.: Withaferin A targets the membrane of Pseudomonas aeruginosa and mitigates the inflammation in zebrafish larvae; an in vitro and in vivo approach. Microb Pathog. 2022, 172:105778. 10.1016/j.micpath.2022.105778
    44. Dikasso D, Makonnen E, Debela A, et al.: In vivo anti-malarial activity of hydroalcoholic extracts from Asparagus africanus Lam In mice infected with Plasmodium berghei. Ethiop J. Health Dev. 2007, 20:112-118. 10.4314/ejhd.v20i2.10021

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2024 Multidisciplinary Reviews

How to cite

Kumar, K., Sarode , A., & Sarode, R. (2024). Harnessing the power of <em>Withania somnifera</em> (Ashwagandha) in oncology and neurodegenerative disorders: A comprehensive review. Multidisciplinary Reviews, (| Accepted Articles). Retrieved from https://malque.pub/ojs/index.php/mr/article/view/2988
  • Article viewed - 33